Awakn Life Sciences Corp. (AWKNF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Awakn Life Sciences Corp. (AWKNF) trades at $0.07 with AI Score 43/100 (Grade C). Awakn Life Sciences Corp. is a biotechnology company focused on researching, developing, and delivering psychedelic medicines to treat addiction. Market cap: $2.71M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for AWKNF: AWKNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AWKNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AWKNF: the 1 perspectives are evenly split.
How is this calculated? →Awakn Life Sciences Corp. (AWKNF) Healthcare & Pipeline Overview
Awakn Life Sciences Corp. is a biotechnology company focused on developing and delivering psychedelic medicines for addiction treatment. They are positioned to address the growing need for innovative mental health solutions, differentiating themselves through research-backed therapies and specialized treatment centers.
What Is the Investment Thesis for AWKNF?
Awakn Life Sciences Corp. presents a compelling investment thesis centered on the growing demand for innovative addiction treatments and the potential of psychedelic medicines. The company's focus on evidence-based research and integrated care positions it to capitalize on the increasing acceptance of psychedelic therapies. Key value drivers include successful clinical trial outcomes, expansion of the treatment center network, and strategic partnerships with healthcare providers. Upcoming catalysts include the results of ongoing clinical trials and regulatory approvals for Awakn's therapies. Potential risks include regulatory hurdles, competition from established pharmaceutical companies, and the need for significant capital investment.
Based on FMP financials and quantitative analysis
AWKNF Key Highlights
- Focus on psychedelic medicines for addiction treatment, addressing a significant unmet need in the healthcare sector.
- Development of integrated treatment centers combining psychedelic-assisted therapy with traditional approaches.
- Active research programs exploring the potential of ketamine and MDMA in treating various addiction disorders.
- Strategic partnerships with healthcare providers to expand the reach of Awakn's therapies.
- Commitment to evidence-based research and ethical practices in the field of psychedelic medicine.
Who Are AWKNF's Competitors?
AWKNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CYBN Cybin Inc. | $8.28 | +1.22% | $413.02M | 47 |
| CMPS COMPASS Pathways plc | $12.94 | -5.03% | $1.24B | 48 |
| MNMD Mind Medicine (MindMed) Inc. | $20.69 | +0.44% | $1.56B | 46 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AWKNF's Key Strengths?
- Focus on psychedelic medicines for addiction treatment.
- Integrated treatment centers combining psychedelic-assisted therapy with traditional approaches.
- Active research programs exploring the potential of ketamine and MDMA.
- Strategic partnerships with healthcare providers.
What Are AWKNF's Weaknesses?
- Limited operating history.
- Dependence on regulatory approvals for psychedelic medicines.
- Need for significant capital investment.
- Competition from established pharmaceutical companies.
What Could Drive AWKNF Stock Higher?
- Results from ongoing clinical trials of ketamine and MDMA therapies.
- Regulatory approvals for Awakn's psychedelic medicines.
- Expansion of the treatment center network across North America and Europe.
- Strategic partnerships with healthcare providers to integrate Awakn's therapies.
- Advancements in research and development of new psychedelic compounds.
What Are the Key Risks for AWKNF?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and uncertainties surrounding psychedelic medicines.
- Competition from established pharmaceutical companies and alternative addiction treatments.
- Negative public perception of psychedelic medicines.
- Adverse side effects from psychedelic therapies.
- Need for significant capital investment to fund research, development, and expansion.
What Are the Growth Opportunities for AWKNF?
- Expansion of Treatment Center Network: Awakn has the opportunity to expand its network of treatment centers across North America and Europe. Each new center increases the company's capacity to deliver its integrated care model, combining psychedelic-assisted therapy with traditional therapeutic approaches. The expansion strategy includes establishing new centers in key markets and partnering with existing healthcare providers to integrate Awakn's therapies into their services. This growth driver is expected to contribute significantly to revenue growth and market share gains.
- Successful Clinical Trial Outcomes: Awakn's research programs are focused on generating robust clinical evidence supporting the safety and efficacy of its therapies. Positive results from ongoing clinical trials could lead to regulatory approvals and increased adoption of Awakn's treatments. The company is exploring the potential of psychedelic compounds like ketamine and MDMA in treating various addiction disorders, including alcohol use disorder, opioid addiction, and behavioral addictions. Successful trial outcomes would validate Awakn's approach and attract further investment and partnerships.
- Strategic Partnerships with Healthcare Providers: Awakn can leverage strategic partnerships with healthcare providers to expand the reach of its therapies. Collaborating with hospitals, clinics, and mental health organizations can facilitate the integration of Awakn's treatments into existing healthcare systems. These partnerships can provide access to a broader patient base and accelerate the adoption of Awakn's therapies. The company is actively seeking partnerships with organizations that share its commitment to evidence-based care and innovative approaches to addiction treatment.
- Regulatory Approvals for Psychedelic Therapies: The regulatory landscape for psychedelic medicines is evolving, with increasing acceptance and potential for regulatory approvals. Awakn is well-positioned to benefit from these developments by pursuing regulatory pathways for its therapies. Obtaining regulatory approvals would validate the safety and efficacy of Awakn's treatments and open up new markets and reimbursement opportunities. The company is closely monitoring regulatory developments and actively engaging with regulatory agencies to advance its therapies.
- Development of New Psychedelic Compounds: Awakn has the opportunity to develop new psychedelic compounds and formulations to expand its product pipeline. Investing in research and development can lead to the discovery of novel therapies with improved efficacy and safety profiles. The company is exploring various psychedelic compounds and delivery methods to address a wider range of addiction disorders. This growth driver is expected to contribute to long-term value creation and competitive advantage.
What Opportunities Does AWKNF Have?
- Expansion of treatment center network.
- Successful clinical trial outcomes.
- Regulatory approvals for psychedelic therapies.
- Development of new psychedelic compounds.
What Threats Does AWKNF Face?
- Regulatory hurdles and uncertainties.
- Competition from alternative addiction treatments.
- Negative public perception of psychedelic medicines.
- Potential for adverse side effects from psychedelic therapies.
What Are AWKNF's Competitive Advantages?
- Intellectual property protection through patents and proprietary formulations.
- Specialized treatment centers providing a unique and integrated care model.
- Strong research and development capabilities.
- Strategic partnerships with healthcare providers.
What Does AWKNF Do?
Awakn Life Sciences Corp. is a biotechnology company pioneering the research, development, and delivery of psychedelic medicines to treat addiction. Founded with the mission to address the significant unmet needs in mental health and addiction treatment, Awakn is focused on creating innovative therapies that can provide lasting solutions for individuals struggling with addiction. The company's core strategy involves rigorous scientific research, clinical trials, and the establishment of specialized treatment centers. Awakn's research programs explore the potential of psychedelic compounds like ketamine and MDMA in treating various addiction disorders, including alcohol use disorder, opioid addiction, and behavioral addictions. These programs are designed to generate robust clinical evidence supporting the safety and efficacy of Awakn's therapies. In addition to research, Awakn is actively developing a network of treatment centers that offer integrated care, combining psychedelic-assisted therapy with traditional therapeutic approaches. These centers aim to provide a supportive and evidence-based environment for patients seeking to overcome addiction. Awakn Life Sciences operates primarily in North America and Europe, targeting markets with high unmet needs in addiction treatment and a growing acceptance of psychedelic therapies. The company is committed to advancing the field of psychedelic medicine through scientific rigor, ethical practices, and a patient-centered approach.
What Products and Services Does AWKNF Offer?
- Researches and develops psychedelic medicines for addiction treatment.
- Conducts clinical trials to evaluate the safety and efficacy of its therapies.
- Establishes and operates specialized treatment centers.
- Offers integrated care combining psychedelic-assisted therapy with traditional approaches.
- Partners with healthcare providers to expand the reach of its therapies.
- Advocates for regulatory approvals of psychedelic medicines.
How Does AWKNF Make Money?
- Develops and patents psychedelic-based treatments for addiction.
- Generates revenue through treatment centers offering psychedelic-assisted therapy.
- Partners with healthcare providers for therapy delivery.
- Out-licenses intellectual property to other companies.
What Industry Does AWKNF Operate In?
Awakn Life Sciences operates within the rapidly evolving biotechnology industry, specifically focusing on psychedelic medicine. The market for addiction treatment is substantial, with millions of individuals worldwide struggling with various forms of addiction. The industry is witnessing a growing interest in alternative therapies, including psychedelic-assisted treatments, driven by the limitations of traditional approaches. Awakn is positioned to capitalize on this trend by developing evidence-based therapies and establishing specialized treatment centers. The competitive landscape includes pharmaceutical companies, biotech firms, and mental health providers.
Who Are AWKNF's Key Customers?
- Individuals struggling with addiction disorders.
- Healthcare providers seeking innovative treatment options.
- Mental health organizations and hospitals.
- Research institutions and pharmaceutical companies.
Awakn Life Sciences Corp. Financial Trajectory
Awakn Life Sciences Corp. (AWKNF) reported $4K in revenue for Q4 2024, a decline of 66.6% compared to the prior quarter. The company recorded a net loss of $376K, with diluted EPS of $-0.01. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, AWKNF averaged $-0.02 in diluted EPS.
Company Profile
Awakn Life Sciences Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Anthony Tennyson. AWKNF has traded publicly since 2021.
How Awakn Life Sciences Corp. Is Valued
Awakn Life Sciences Corp. carries a market capitalization of $2.71M, placing it in the micro-cap category. Relative to its peer group, AWKNF's quantitative score of 43/100 is below the peer average of 60/100.
F-Score 2/9Financial Health
Awakn Life Sciences Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
FY2027 estForward Outlook
Wall Street analysts project Awakn Life Sciences Corp. revenue of about $59.3M for fiscal 2027, with EPS near $-0.13.
AWKNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Awakn's focus on psychedelic-assisted therapy for addiction is gaining traction, aligning with a growing acceptance of alternative mental health treatments.
- Recent insider buying suggests confidence in the company's long-term prospects and strategic direction.
- The community is buzzing about potential partnerships and expansion plans, indicating positive future growth.
- Awakn's unique approach to treating addiction positions them well in a market ripe for innovation.
Bear Case
- Regulatory hurdles and the evolving legal landscape for psychedelic treatments create significant uncertainty for Awakn.
- Community sentiment reveals concerns about the company's ability to scale operations effectively and manage costs.
- Market perception is cautious due to the speculative nature of the psychedelic sector and the lack of long-term clinical data.
- Increased competition in the psychedelic-assisted therapy space may erode Awakn's market share and pricing power.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2024 | $3,670 | -$376,126 | -$0.01 |
| Q3 2024 | $10,994 | -$360,993 | -$0.01 |
| Q2 2024 | $20,679 | -$544,815 | -$0.01 |
| Q1 2024 | $21,818 | -$1M | -$0.03 |
Based on FMP financials and quantitative analysis
AWKNF Latest News
No recent news available for AWKNF.
AWKNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AWKNF.
Price Targets
Wall Street price target analysis for AWKNF.
AWKNF MoonshotScore
What does this score mean?
The MoonshotScore rates AWKNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
AWKNF OTC Market Information
AWKNF trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
What Investors Ask About Awakn Life Sciences Corp. (AWKNF) — Healthcare
What does AWKNF do?
Awakn Life Sciences Corp. is a biotechnology company focused on researching, developing, and delivering psychedelic medicines to treat addiction. The company's core strategy involves rigorous scientific research, clinical trials, and the establishment of specialized treatment centers. Awakn's research programs explore the potential of psychedelic compounds like ketamine and MDMA in treating various addiction disorders, including alcohol use disorder, opioid addiction, and behavioral addictions. The company aims to address unmet needs in mental health and addiction treatment through innovative therapies.
What do analysts say about AWKNF stock?
Analyst coverage of Awakn Life Sciences Corp. is currently limited, reflecting the early stage of the company and the emerging nature of the psychedelic medicine industry. Key valuation metrics include the potential market size for addiction treatment, the success of clinical trials, and the company's ability to secure regulatory approvals. Growth considerations include the expansion of the treatment center network, strategic partnerships, and advancements in research and development. Investors should conduct their own due diligence and consider the risks and uncertainties associated with investing in a biotechnology company in a nascent industry.
What are the main risks for AWKNF?
The main risks for Awakn Life Sciences Corp. include regulatory hurdles and uncertainties surrounding psychedelic medicines, competition from established pharmaceutical companies and alternative addiction treatments, negative public perception of psychedelic medicines, and potential adverse side effects from psychedelic therapies. The company also faces the risk of needing significant capital investment to fund research, development, and expansion. Investors should carefully consider these risks before investing in Awakn Life Sciences Corp.
What are the key factors to evaluate for AWKNF?
Awakn Life Sciences Corp. (AWKNF) holds an AI score of 43/100 (low). Not financial advice.
How frequently does AWKNF data refresh on this page?
AWKNF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AWKNF's recent stock price performance?
Awakn Life Sciences Corp. (AWKNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on psychedelic medicines for addiction treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AWKNF overvalued or undervalued right now?
Valuing Awakn Life Sciences Corp. (AWKNF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AWKNF?
Before investing in Awakn Life Sciences Corp. (AWKNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The psychedelic medicine industry is rapidly evolving, and the regulatory landscape is uncertain.